EGT-101 - ESTEVE/Universitat Autonoma de Barcelona

Drug Profile

EGT-101 - ESTEVE/Universitat Autonoma de Barcelona

Alternative Names: AAV9-CAG-coh-SGSH; AAV9-hsulfamidase; NAV rAAv9 sulfamidase gene therapy

Latest Information Update: 30 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Universitat Autonoma de Barcelona
  • Developer ESTEVE; Universitat Autonoma de Barcelona
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis III
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Mucopolysaccharidosis III

Most Recent Events

  • 29 Apr 2016 Phase-I/II clinical trials in Mucopolysaccharidosis III (In children, In adolescents) in Spain (Intracerebroventricular) (EudraCT2015-000359-26)
  • 25 Feb 2016 Preclinical trials in Mucopolysaccharidosis III in Spain (Intracerebroventricular)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top